Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.56 |
| ▸ | HTR3B | O95264 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659557 | 0.90 | HTR6 (0.62) | HTR6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4658417 | 0.89 | HTR3E (0.69) | HTR6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4659386 | 0.86 | HTR6 (0.60) | HTR6 | |
| SCHEMBL4658341 | 0.85 | HTR6 (0.72) | HTR6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4658330 | 0.85 | HTR6 (0.72) | HTR6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4658523 | 0.83 | HTR6 (0.60) | HTR6 | |
| SCHEMBL4658392 | 0.83 | HTR6 (0.72) | HTR6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8090756 | 0.83 | HTR6 (0.63) | HTR6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13979786 | 0.83 | HTR6 (0.65) | HTR6HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL28920424 | 0.82 | MAPT (0.59) | HTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423106-B1 | ARYLSULFONYL DERIVATIVES WITH 5-HT 6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2008-12-17 | — | — | EP | claimed |
| US-6825202-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-30 | — | — | US | claimed |
| US-20030069254-A1 | New arylsulfonyl derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | claimed |
| EP-1423106-B1 | ARYLSULFONYL DERIVATIVES WITH 5-HT 6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2008-12-17 | — | — | EP | disclosed |
| EP-1423106-B1 | ARYLSULFONYL DERIVATIVES WITH 5-HT 6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-6825202-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-30 | — | — | US | disclosed |
| EP-1423106-A1 | ARYLSULFONYL DERIVATIVES WITH 5-HT 6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| US-20030069254-A1 | New arylsulfonyl derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2003014097-A1 | ARYLSULFONYL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069254-A1 | New arylsulfonyl derivatives with 5-HT6 receptor affinity | HTR6, HTR1A, HTR4 | HTR6 1/4885HTR3E 13/4885HTR3B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.